Saroja Pharma Industries India Ltd - Stock Valuation and Financial Performance

BSE: 0 | NSE: SAROJA | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Saroja Pharma Ind

M-Cap below 100cr DeciZen not available

Saroja Pharma Industries India stock performance -

mw4me loader
P/E Ratio (SA):
26.29
Market Cap:
23.1 Cr.
52-wk low:
0
52-wk high:
0

Is Saroja Pharma Industries India Ltd an attractive stock to invest in?

1. Is Saroja Pharma Industries India Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Saroja Pharma Industries India Ltd is a below average quality company.

2. Is Saroja Pharma Industries India Ltd undervalued or overvalued?

The key valuation ratios of Saroja Pharma Industries India Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Saroja Pharma Industries India Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Saroja Pharma Industries India Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Saroja Pharma Ind:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Saroja Pharma Industries India Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'21Mar'22Mar'23TTM
ROCE % 34.6%33.7%22.1%-
Value Creation
Index
1.51.40.6-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 36.755.650.241
Sales YoY Gr.-51.8%-9.8%-
Adj EPS 55.63.53.72.2
YoY Gr.--93.7%4.3%-
BVPS (₹) 7213.717.335.3
Adj Net
Profit
0.711.11
Cash Flow from Ops. -1.1-3.72.2-
Debt/CF from Ops. -2.9-1.74.7-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANANA-9.8%
Adj EPS NANANA4.3%
BVPSNANANA26.3%
Share Price - - - -2.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'21Mar'22Mar'23TTM
Return on
Equity %
77.341.523.68.3
Op. Profit
Mgn %
3.63.85.6NAN
Net Profit
Mgn %
21.92.12.2
Debt to
Equity
3.21.52-
Working Cap
Days
0751150
Cash Conv.
Cycle
041670

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 2.00

Return on Equity has declined versus last 3 years average to 8.30%

Sales growth has been subdued in last 3 years 0.00%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Saroja Pharma Industries India Ltd.

Standalone Consolidated
TTM EPS (₹) 2.2 -
TTM Sales (₹ Cr.) 40.7 -
BVPS (₹.) 35.3 -
Reserves (₹ Cr.) 10 -
P/BV 1.62 -
PE 26.29 -
From the Market
52 Week Low / High (₹) 0.00 / 0.00
All Time Low / High (₹) - / -
Market Cap (₹ Cr.) 23.1
Equity (₹ Cr.) 4
Face Value (₹) 10
Industry PE 47.6

Management X-Ray of Saroja Pharma Ind:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Saroja Pharma Ind

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23
Sales36.6655.6350.19
Operating Expenses 35.3653.5347.47
Manufacturing Costs1.331.861.06
Material Costs32.0248.5044.31
Employee Cost 0.550.730.83
Other Costs 1.472.441.27
Operating Profit 1.302.102.72
Operating Profit Margin (%) 3.6%3.8%5.4%
Other Income 0.090.320.16
Interest 0.330.801.32
Depreciation 0.020.050.07
Exceptional Items 000
Profit Before Tax 1.041.581.49
Tax 0.300.440.43
Profit After Tax 0.731.141.06
PAT Margin (%) 2.0%2.0%2.1%
Adjusted EPS (₹)56.33.93.6
Dividend Payout Ratio (%)0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 0.944.035.09
Share Capital 0.010.232.94
Reserves 0.933.802.15
Minority Interest000
Debt3.026.1410.19
Long Term Debt1.421.702.81
Short Term Debt1.604.447.38
Trade Payables4.155.315.86
Others Liabilities 0.120.040.20
Total Liabilities 8.2215.5121.34

Fixed Assets

Gross Block0.120.422.36
Accumulated Depreciation0.030.070.14
Net Fixed Assets0.090.342.22
CWIP 001.79
Investments 00.040.14
Inventories0.660.473.87
Trade Receivables7.2213.9811.11
Cash Equivalents 00.260.36
Others Assets0.250.421.86
Total Assets 8.2215.5121.34

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23
Cash Flow From Operating Activity -1.05-3.672.19
PBT 1.041.581.49
Adjustment 0.350.841.37
Changes in Working Capital -2.13-5.65-0.25
Tax Paid -0.30-0.44-0.42
Cash Flow From Investing Activity -0.05-0.34-4.82
Capex -0.05-0.30-3.73
Net Investments 0-0.04-0.10
Others 00-1
Cash Flow From Financing Activity 1.034.272.73
Net Proceeds from Shares 01.950
Net Proceeds from Borrowing 000
Interest Paid -0.33-0.80-1.32
Dividend Paid 000
Others 1.363.124.05
Net Cash Flow -0.070.260.10
PARTICULARSMar'21Mar'22Mar'23
Ratios
ROE (%)78.1445.9523.28
ROCE (%)34.5933.7322.1
Asset Turnover Ratio4.464.692.72
PAT to CFO Conversion(x)-1.44-3.222.07
Working Capital Days
Receivable Days727091
Inventory Days7416
Payable Days473646

Saroja Pharma Industries India Ltd Stock News

Saroja Pharma Industries India Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Saroja Pharma Ind on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Saroja Pharma Ind stood at ₹23.06.
The latest P/E ratio of Saroja Pharma Ind as of 01-Jan-1970 05:30 is 26.29.
The latest P/B ratio of Saroja Pharma Ind as of 01-Jan-1970 05:30 is 1.62.
The 52-week high of Saroja Pharma Ind is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Saroja Pharma Ind is ₹40.67 ( Cr.) .

About Saroja Pharma Industries India Ltd

Saroja Pharma Industries India was originally incorporated as Private Limited, under the Companies Act, 2013 (Companies Act) in the name and style of ‘Saroja Pharma Industries India Private Limited’ on January 14, 2019 under the provisions of the Companies Act, 2013 vide Certificate of Incorporation issued by the Registrar of Companies, Mumbai, Maharashtra. Later on, company was converted into public limited company and due to the conversion, the name of the company name was changed to ‘Saroja Pharma Industries India Limited’ and a fresh Certificate of Incorporation dated April 18, 2023 was issued by the Registrar of Companies, Mumbai, Maharashtra.

The company is amongst the leading traders, exporter and suppliers of Specialty Chemicals. The offered range is widely praised for its superior effectiveness, shelf life and perfect composition. The company was incorporated with the objective of the best service deliverance in chemical trading with the best premium pharmaceutical companies in India and abroad for cost effective human and veterinary medicine. The company trade in Pharma API, Pharma Intermediates, Chemicals, Solvents used for pharmaceutical products human and veterinary medicine. The Company was formed with a mission being providing clientele specification based approved product at a competitive pricing with hassle free dispatch within India or aboard contributing to cost effectiveness in end product for human and veterinary medicine.

The product demand by its clientele is manufactured as per their specifications by its suppliers initially in sample size thereafter on clients testing and approving the order is finalized. The approved specified product is manufactured for the order quantity to be dispatched by the appropriate mode of transport within India or abroad. Since its inception, Saroja Pharma Industries India has witnessed a substantial expansion in its clientele base over the past two years. This growth has propelled the company to venture into the manufacturing of API Pharma products, for veterinary use. By broadening its product portfolio, Saroja Pharma Industries India aims to provide a comprehensive range of pharmaceutical solutions that cater to the diverse needs of its expanding customer base. This strategic move not only enhances the company's value proposition but also reinforces its commitment to delivering affordable healthcare solutions globally.

Business area of the company 

The company is engaged into the business of trading of pharma products like pharma API, Pharma Intermediary and Pharma chemicals.

Products of the company 

Chemical

  • Liquid bromine 
  • Ethyl acetate 
  • Thionyl chloride 
  • Para nitro phenol 
  • Toluene N.G 
  • Benzyl chloride

Active Pharmaceutical Ingredient (API)

  • Oxyclozanide BP Vet
  • Bromhexine HCL BP Grade
  • Triclabendazole
  • Fenbendazole BP Vet
  • Nitroxynil BP Vet
  • Oxfendazole BP Vet
  • Albendazole USP
  • Rafoxanide BP Vet
  • Febantel EP

Pharma Intermediary

History and milestones 

  • 2019: Incorporation of the company viz. Saroja Pharma Industries India Private Limited.
  • 2023: Conversion of the company’s status from Private Limited to Limited Company to Saroja Pharma Industries India Limited. 

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.